Effects of IQ on whole-blood coagulation. Mean change from baseline in (A) clot initiation time (reaction-time or R-time) and (B) clot formation time (K time) showing significant prolongation from the baseline value after IQ treatment (ANCOVA, ∗P = .04 and ∗P = .02, respectively). (C) Fibrin crosslinking determined by the α-angle acuteness signified by the maximal amplitude showing significant reduction from the baseline value after IQ treatment (ANCOVA, ∗∗∗∗P = .0001). However, (D) clot strength (MA) was not affected by IQ treatment (P = .09). (E) Mean change from the baseline in whole-blood CI assessed by TEG showed a significant reduction in the IQ group compared with in the placebo group (ANCOVA, ∗P = .03; IQ, n = 22; placebo, n = 22). AU, arbitrary units; MA, maximum amplitude.